

## RISK FACTORS OF MALIGNANCIES IN INFLAMMATORY BOWEL DISEASE: A SINGLE CENTER EXPERIENCE

Fabiana Zingone

UEG Week Copenhagen 2023

Poster

IBD

October 15, 2023

**A retrospective study of 2213 IBD patients found azathioprine use for more than 4 years was associated with melanoma and breast cancer, while biological therapy showed no association with malignancies.**

### KEY POINTS

- Among 153 IBD patients with malignancy, the most frequent cancers were breast cancer (2.7% of females), melanoma (1.1%), colorectal cancer (1%), and non-melanoma skin cancer (0.7%), with mean time from IBD diagnosis to first tumor of 15 years.
- Patients taking azathioprine at cancer diagnosis for more than 4 years showed significantly higher rates of melanoma (12.5% vs 0%,  $p<0.01$ ) and breast cancer (14.8% vs 0%,  $p<0.01$ ) compared to controls.
- A lower percentage of patients with colon, breast, and prostate cancers had taken biological therapy before cancer occurrence compared to controls (13%, 4%, and 9.1% vs 44%,  $p<0.01$ ), with the authors concluding biological therapy was not associated with malignancies.
- Patients with colon cancer were younger at IBD diagnosis ( $31.0\pm15.8$  vs  $38.9\pm0.8$  years,  $p<0.001$ ), while patients with prostate and urinary cancer were older ( $49.6\pm13.7$  vs  $38.9\pm0.8$  years,  $p<0.001$ ).
- This retrospective case-control analysis may be relevant for gastroenterologists managing long-term immunosuppressive therapy in IBD patients.

VIEW THIS CONTENT ON GUTFLIX

<https://gutflif.eu/search/d/091c9ffe-743c-11ee-8600-0242ac140004>



**AI-generated summary**

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.